Nifedipine-retard alone and incombination with metoprolol: comparative efficacy andsafety in patients with arterial hypertension

Cite item

Full Text


Aim. To compare efficacy and safety of nifedipin-retard (cordaflex-retard, Egis, Hungary) used in
monotherapy and in combination with metoprolol (egilok, Egis, Hungary) in patients with arterial hypertension (AH).
Material and methods. The study included 20 patients with AH stage I-II (12 males, 8 females,
mean age 57.3 years, mean duration of the disease 8.6 years). Nifedipin-retard was given in a daily
dose 40 mg/day (20 mg twice a day) in monotherapy and 20 mg/day in combination with metoprolol
which was administered 50 mg twice a day (a daily dose 100 mg/day). The control examination consisted of a physical examination, measurement of arterial pressure (AP) by Korotkov, registration of
heart rate, ECG, 24-h AP monitoring, echocardiography.
Results. By 24-h AP monitoring, a 4-week treatment with nifedipin-retard alone resulted in lowering
of systolic arterial pressure. The combined treatment produced a more pronounced fall both in systolic
and diastolic pressure. Diastolic left-ventricular function improved in combined therapy. Side effects
observed in nifedipin-retard monotherapy got much more weaker when this drug combined with metoprolol.
Conclusion. Combination of nifedipin-retard with metoprolol provides better clinical response and tolerance than monotherapy with nifedipin-retard.


  1. Gong L., Zhang W., Zhu J. et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J. Hypertens. 1996; 14: 1237-1245.
  2. Hansson L., Zanchetti A., Carruthers S. G. et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
  3. Joint National Committee on Prevention, Detection, Evalua- tion, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Commitee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch. Intern. Med. 1997; 157: 2413-2446.
  4. World Health Organization-International Society of Hypertension. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines subcommitee. J. Hypertens 1999; 17: 151.
  5. Профилактика, диагностика и лечение первичной артериальной гипертонии в Российской Федерации (ДАГ-1). Клин, фармакол. и фармакотер. 2000; 3: 5-31.
  6. ANAES Agence Nationale d'Accreditation et d'Evaluation en Sante Recommandations. 2000. 1-17.
  7. White W. В., Dey H. M., Schulman P. Assessment of the daily pressure load as a determine of cardiac function in patients with mild-to moderate hypertension. Am. Heart J. 1989; 118: 782-795.
  8. Strauer B. E., Schwartzkopff B. Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve. Am. J. Hypertens. 1998; 11: 879-881.

Copyright (c) 2003 Isaikina O.Y., Gorbunov V.M., Andreeva G.F., Dmitrieva N.A., Martsevich S.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies